Sutent Related Clinical Trials
Ph I SU011248 + Irinotecan in Treatment of Pts w MG [Active, not recruiting]
Study of Combination of Sirolimus and Sutent in Patients With Advanced Solid Tumors Non-Curable With Standard Therapy [Active, not recruiting]
A Study To Find The Best Doses Of SU011248 (Sunitinib) And Capecitabine When These Drugs Are Administered Together [Active, not recruiting]
Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy [Recruiting]
Study of SU011248 in Combination With Docetaxel in Patients With Metastatic Breast Cancer [Active, not recruiting]
Study of SU11248 in Men With Advanced Prostate Cancer [Completed]
A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma [Recruiting]
A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma [Recruiting]
Clinical Study of SU 11248 (Sutent) Combined With Standard Chemotherapy in Patients With FLT3 Mutated AML Over 60 Years [Recruiting]
Bevacizumab With or Without Sunitinib in Sunitinib-Refractory Renal Cell Carcinoma [Recruiting]
A Phase I/II Study of Sunitinib Malate (SU011248) In Patients With Gastrointestinal Stromal Tumor (GIST) [Active, not recruiting]
A Phase I Study of Bevacizumab and Sunitinib in Metastatic Renal Cell Carcinoma Patients [Completed]
Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer [Recruiting]
Pre-Surgical Sutent in Renal Cell Carcinoma (RCC) [Recruiting]
Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma [Recruiting]
Study In Patients With Kidney Cancer Treated With Sutent [Recruiting]
SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage IV Colorectal Cancer [Active, not recruiting]
Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer [Recruiting]
Sutent Adjunctive Treatment of Differentiated Thyroid Cancer [Recruiting]
Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma [Recruiting]
Study of SutentŪ/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas [Not yet recruiting]
A Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma [Recruiting]
Phase 2 Study of PanzemŪ NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma [Active, not recruiting]
Combination of Recombinant Human IL-21 (rIL-21) and Sunitinib in Stage IV Renal Cell Carcinoma Patients
Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors [Recruiting]
Capiri-sutent Phase-1 in Advanced Colo-rectal Cancer [Recruiting]
Predictive Value of Drug Elimination Gene Polymorphisms on Clearance and Dose Adjustment of Sunitinib in Cancer Patients [Recruiting]
Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic or Unresectable Kidney Cancer [Recruiting]
Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma [Recruiting]
Clinical Trial of Sutent to Treat Metastatic Melanoma [Recruiting]
Neoadjuvant Sunitinib Treatment for Metastatic Clear Cell Renal Cell Carcinoma (RCC) [Recruiting]
Evaluation of Patients With Bulky GIST Using Sunitinib [Recruiting]
Sunitinib and Radiation in Patients With Resectable Soft-tissue Sarcoma [Recruiting]
Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino Patients [Recruiting]
Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer [Recruiting]
Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) [Recruiting]
Study of Efficacy and Safety of Sunitinib Given on an Individualized Schedule [Recruiting]
A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor [Recruiting]
Safety Study of Preoperative Sunitinib and Radiation in Soft Tissue Sarcoma [Recruiting]
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. [Recruiting]
Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma [Recruiting]
Study Evaluating Two Loading Regimens of Sunitinib Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC) [Recruiting]
Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma [Recruiting]
Treatment With SU11248 in Patients With Neuroendocrine Tumors
SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma [Recruiting]
Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma [Recruiting]
Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma [Recruiting]
Temodar and Sutent as Therapy for Melanoma [Recruiting]
Phase I Study of Imatinib Mesylate and SU011248 (Sunitinib) for Patients With GIST [Not yet recruiting]
Randomized Phase II Study of Sunitinib Administered as 4/2 vs. 2/1 Schedule in Advanced RCC [Recruiting]
Erlotinib and Sunitinib in NSCLC [Recruiting]
Sunitinib in Treating Patients With Myelodysplastic Syndromes [Recruiting]
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas [Recruiting]
A Phase I/II Study of Sunitinib and Dacarbazine [Recruiting]
Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus [Suspended]
Interaction Study of Rapamycin and Sunitinib in Patients With Advanced Cancers [Completed]
SU011248 in Advanced Hepatocellular Carcinoma [Recruiting]
Sunitinib in Refractory Adrenocortical Carcinoma [Recruiting]
Bevacizumab and Sunitinib in Treating Patients With Solid Tumors [Recruiting]
Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma [Recruiting]
A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer [Recruiting]
A Study To Find The Best Doses Of SU011248 And Gemcitabine When Given Together To Patients With Advanced Solid Tumors [Recruiting]
A Safety Study Of Sunitinib In Combination With Pemetrexed In Patients With Advanced Solid Malignancies [Recruiting]
Sunitinib in Treating Patients With Newly Diagnosed Stage II or Stage III Breast Cancer That Can Be Removed by Surgery [Recruiting]
A Phase Ib Study of Rad001 and Sutent to Treat Renal Cell Carcinoma [Recruiting]
SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme [Recruiting]
Phase-II Study of SU011248 (Sunitinib)in Male Patients With Relapsed or Cisplatin-Refractory Germ Cell Cancer [Not yet recruiting]
Treatment Protocol for Patients Continuing From SU011248 Protocols [Recruiting]
Randomized Multicenter Trial With SU11248 Evaluating Dosage,Tolerability,Toxicity and Effectiveness of a Multitargeted Receptor Tyrosine Kinase Inhibitor [Recruiting]
Non-Interventional Study (NIS) In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With SUTENTŪ [Not yet recruiting]
A Clinical Trial Comparing Efficacy and Safety of Sunitinib and Capecitabine [Recruiting]
Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RCC) [Recruiting]
Sutent + Taxol for Advanced Esophageal Cancer [Recruiting]
Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Prostate Cancer [Recruiting]
Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer [Recruiting]
An Exploratory Study of the Biological and Clinical Activity of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer [Recruiting]
Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow [Recruiting]
Study Of Sunitinib Plus FOLFOX In Patients With Solid Tumors [Recruiting]
SU11248 as Consolidation After Response to Taxanes in Metastatic Breast Cancer [Recruiting]
Study Of SU011248 In Combination With Docetaxel And Trastuzumab In Patients With Advanced Breast Cancer HER-2 Positive [Recruiting]
Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma [Recruiting]
A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid Tumors [Recruiting]
Sunitinib in Treating Young Patients With Refractory Solid Tumors [Suspended]
Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma [Recruiting]
Sunitinib Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With Extensive-Stage Small Cell Lung Cancer [Recruiting]
Efficacy And Safety Of Sunitinib In Women With Advanced Breast Cancer [Recruiting]
Sutent Maintenance After Response to Taxotere [Recruiting]
Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors [Recruiting]
Sunitinib, Cisplatin or Carboplatin, and Etoposide in Treating Patients With Extensive-Stage Small Cell Lung Cancer [Recruiting]
Sunitinib in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery [Recruiting]
Study of Safety and Effects of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma [Recruiting]
Study Of SU011248 In Combination With Paclitaxel/Carboplatin In Patients With Advanced Solid Tumors [Recruiting]
Sunitinib in Treating Patients With Unresectable, Locally Advanced or Metastatic Cervical Cancer [Recruiting]
Sunitinib in Treating Patients With Advanced or Metastatic Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer [Recruiting]
Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma [Recruiting]
Sunitinib in Treating Patients With Relapsed or Refractory Diffuse or Mediastinal Large B-Cell Lymphoma [Recruiting]
A SU011248 Expanded Access Protocol for Systemic Therapy of Patients With Metastatic Renal Cell Carcinoma Who Are Ineligible for Participation in Other SU011248 Protocols But May Derive Benefit From Treatment With SU011248 [Recruiting]
Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma [Recruiting]
Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine [Recruiting]
Sunitinib in Patients With Renal Cells Carcinoma Metastasic or Locally Avanced in Patients Not Candidates to Curative Previous Nefrectomy [Recruiting]
Thyroid Cancer and Sunitinib [Recruiting]
|
